Geneticure has announced that the US Patent and Trademark Office has granted a patent for a genetic-based weighted algorithm model for predicting response to renal denervation.
This patent protects Geneticure’s proprietary method of using a patient’s genetic profile to predict their likelihood of benefiting from renal denervation—a minimally invasive procedure used to treat hypertension.
“Renal denervation has demonstrated the ability to reduce blood pressure in certain patients, with other’s experiencing no change or an increase in blood pressure post-denervation,” said Scott Snyder, chief executive officer of Geneticure. “Prior to Geneticure’s research, a reliable method of predicting the response had not yet emerged and regardless of the denervation method, the changes in blood pressure have been variable across patient populations. Our technology has proven to identify the individuals most likely to respond, enabling more targeted use of this emerging therapy with increased prospects for adoption and payer coverage.”
The patented method leverages specific genetic markers combined with a proprietary weighted algorithm to determine responsiveness to renal denervation, enabling physicians to make informed treatment decisions beyond traditional risk-factor assessments.
This newly issued patent expands Geneticure’s growing intellectual property portfolio in the field of pharmacogenomics and device response prediction, further positioning the company at the forefront of personalised hypertension management, a press release states.
